... Koseci; Mehmet Ali Nahit Sendur Introduction: In the adjuvant treatment of low-risk stage III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since there are no data on this practice in the literature, we have no idea how often...

... chemotherapy. Methods: Between April 2014 and August 2018, we enrolled 165 cancer patients at our outpatient chemotherapy center who were undergoing capecitabine chemotherapy. Variables related to the development of HFS were extracted from the clinical records of patients for use in regression analysis. HFS...

...) of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer. Method: Patients received irinotecan and oxaliplatin (85 mg/m 2 ) on day 1, and capecitabine (1,000 mg/m 2 orally twice daily) on days 1–7 of a biweekly schedule...

... Delconte; Filippo de Braud; Vincenzo Mazzaferro; Maria Di Bartolomeo Objectives: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ...

... analysis aims to evaluate the effectiveness and tolerability of early maintenance capecitabine administrated to patients with MPC treated with first-line FOLFIRINOX. Methods: 103 patients treated for MPC between November 2009 and July 2014 were retrospectively identified in our institution. Among them, 30...

...Masahiro Kashiwaba; Toru Inaba; Hideaki Komatsu; Kazushige Ishida; Ryoko Kawagishi; Yusuke Matsui; Noriyuki Uesugi; Tamotsu Sugai; Go Wakabayashi Objective: A dose escalation study of biweekly irinotecan (CPT-11) combined with capecitabine was performed to determine the maximum tolerated dose (MTD...

...Suayib Yalcin; Ruchan Uslu; Faysal Dane; Ugur Yilmaz; Nurullah Zengin; Evin Buyukunal; Suleyman Buyukberber; Celalettin Camci; Orhan Sencan; Sadettin Kilickap; Fatih Ozdener; Duygu Cevik Objective: It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine...

...Francesco Perri; Paolo Muto; Angela Argenone; Franco Ionna; Francesco Longo; Franco Fulciniti; Fabio Sandomenico; Antonio Daponte; Francesco Caponigro Objectives: To replace 5-fluorouracil with capecitabine within a trial of induction chemotherapy followed by cetuximab plus radiotherapy (RT...

...-PET/CT as a surrogate biomarker of the pathological complete response in locally advanced rectal cancer treated with neoadjuvant chemoradiation. Methods: T3–4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7–8 weeks...

... a partial response (40% decrease) to a novel regimen of capecitabine and temozolomide (CAPTEM) and progression-free survival of 18 months. He had minor grade 1 toxicities and no grade 2, 3 or 4 toxicities. Discussion: The history and treatment options for MEN-1/2 cancers are reviewed, as well as the data...

... rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients. Methods: Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and measurable disease were enrolled...

.../gemcitabine (arm A: docetaxel 75 mg/m 2 on day 1, gemcitabine 1,000 mg/m 2 on days 1 and 8) or docetaxel/capecitabine (arm B: docetaxel 75 mg/m 2 on day 1, capecitabine 1,250 mg/m 2 twice daily on days 1–14); both chemotherapy regimens were repeated every 21 days. The primary objective of the study...

...K. Amarantidis; N. Xenidis; L. Chelis; E. Chamalidou; P. Dimopoulos; P. Michailidis; A. Tentes; S. Deftereos; M. Karanikas; A. Karayiannakis; S. Kakolyris Objective: In the present phase II study, we evaluated the efficacy and safety of a docetaxel-oxaliplatin-capecitabine combination as a first...

...Thomas Bachelot; Agathe Bajard; Isabelle Ray-Coquard; Jocelyne Provencal; David Coeffic; Cécile Agostini; Martial Boisseau; Régis Kaphan; Dominique Dramais; Corina Oprea; Rose-Marie Ferri-Dessens; Jean-Paul Guastalla; David Perol Objective: To assess the efficacy of capecitabine plus docetaxel (XT...

... with capecitabine-based chemotherapy. Methods: Twenty-nine Swiss oncologists recruited patients receiving capecitabine, either as monotherapy or in combination with other chemotherapeutic agents, in a prospective fashion. Patients recorded both their capecitabine intake and any adverse effects each day in patient...

...A.A. Kotsori; S. Dolly; A. Sheri; M. Parton; N. Shaunak; S. Ashley; G. Walsh; S. Johnston; I.E. Smith Background: Recent data suggest that capecitabine may have little efficacy in women with metastatic triple negative breast cancer (TNT). We have therefore retrospectively analysed capecitabine...

...G. Perrocheau; J. Bennouna; M. Ducreux; M. Hebbar; M. Ychou; G. Lledo; T. Conroy; S. Dominguez; R. Faroux; V. Florentin; J.Y. Douillard Objective: In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy...

...Shelly S. Lo; Alok A. Khorana; Milind Javle; Sheryl Simon; Gauri Kiefer; Kiran Rajasenan; Hong Wang; Alexander Hantel; Michelle Shayne; Jimmy Hwang; Amy Schmotzer; Ramesh K. Ramanathan Objective: Docetaxel and capecitabine are active agents in advanced gastric and gastroesophageal (GE) carcinomas...

... and its symptoms. High activity, oral administration and no alopecia make capecitabine monotherapy attractive in slowly evolving disease. Methods: We retrospectively analysed 226 patients who had received single-agent capecitabine as 1st-line chemotherapy at our institution. Results: The median interval...

...Edward Chu; Nianwen Shi; Wenhui Wei; Johanna C. Bendell; Thomas Cartwright Objective: To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection. Methods: This retrospective...